Alzheimer disease: therapeutic strategies
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Boston
Birkhäuser
1994
|
| Schriftenreihe: | Advances in Alzheimer disease therapy
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIV, 509 S. graph. Darst. |
| ISBN: | 0817637575 3764337575 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV009962156 | ||
| 003 | DE-604 | ||
| 007 | t | ||
| 008 | 941223s1994 d||| |||| 00||| eng d | ||
| 016 | 7 | |a 943342449 |2 DE-101 | |
| 020 | |a 0817637575 |9 0-8176-3757-5 | ||
| 020 | |a 3764337575 |9 3-7643-3757-5 | ||
| 035 | |a (OCoLC)31011493 | ||
| 035 | |a (DE-599)BVBBV009962156 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-29 |a DE-29T |a DE-19 |a DE-188 | ||
| 050 | 0 | |a RC523 | |
| 082 | 0 | |a 616.8/31 |2 20 | |
| 084 | |a YG 4015 |0 (DE-625)153494:12921 |2 rvk | ||
| 245 | 1 | 0 | |a Alzheimer disease |b therapeutic strategies |c Ezio Giacobini ... ed. |
| 264 | 1 | |a Boston |b Birkhäuser |c 1994 | |
| 300 | |a XIV, 509 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a Advances in Alzheimer disease therapy | |
| 650 | 4 | |a Alzheimer, Maladie d' - Chimiothérapie | |
| 650 | 4 | |a Alzheimer, Maladie d' - Physiopathologie | |
| 650 | 4 | |a Alzheimer, Maladie d' - Traitement | |
| 650 | 4 | |a Alzheimer Disease |x physiopathology | |
| 650 | 4 | |a Alzheimer Disease |x therapy | |
| 650 | 4 | |a Alzheimer's disease |x Chemotherapy | |
| 650 | 4 | |a Alzheimer's disease |x Pathophysiology | |
| 650 | 4 | |a Alzheimer's disease |x Treatment | |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Alzheimerkrankheit |0 (DE-588)4112510-1 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Alzheimerkrankheit |0 (DE-588)4112510-1 |D s |
| 689 | 0 | 1 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Alzheimerkrankheit |0 (DE-588)4112510-1 |D s |
| 689 | 1 | 1 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Giacobini, Ezio |d 1929- |e Sonstige |0 (DE-588)114737282 |4 oth | |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006602217&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-006602217 | |
Datensatz im Suchindex
| _version_ | 1807774093661962240 |
|---|---|
| adam_text |
CONTENTS
INTRODUCTIONS
DEVELOPMENT
OF
DRUGS
FOR
ALZHEIMER
THERAPY:
A
DECADE
OF
PROGRESS
.
1
EZIO
GIACOBINI
AND
ROBERT
BECKER
EPIDEMIOLOGY
OF
AD:
IMPACT
ON
THE
TREATMENT
.
8
LUIGI
AMADUCCI
AND
LAURA
FRATIGLIONI
PART
I.
NEUROPATHOLOGIC
AND
GENETIC
BASIS
OF
AD
TREATMENT
NEUROPATHOLOGICAL
BASES
OF
ALZHEIMER
DISEASE,
IMPLICATIONS
FOR
TREATMENT
.
17
HENRYK
M.
WISNIEWSKI
AND
JERZY
WEGIEL
AMYLOID
DEPOSITION
AS
THE
CENTRAL
EVENT
IN
THE
ETIOLOGY
AND
PATHOGENESIS
OF
ALZHEIMER
'
S
DISEASE
.
23
JOHN
HARDY
AND
KAREN
DUFF
ROLE
OF
ABNORMAL
PHOSPHORYLATION
OFTAU
IN
NEUROFIBRILLARY
DEGENERATION:
IMPLICATIONS
FOR
ALZHEIMER
THERAPY
.
28
KHALID
IQBAL
AND
INGE
GRUNDKE-IQBAL
OLFACTORY
BULB
INVOLVEMENT
IN
AD:
AN
EARLY
CHANGE?
.
34
ROBERT
G.
STRUBLE,
MONA
GHOBRIAL
AND
LARRY
F.
HUGHES
ALZHEIMER
DISEASE
-
A
SPIROCHETOSIS?
.
41
JUDIT
MIKLOSSY
PART
N.
THERAPEUTICAL
STRATEGIES
TO
ARREST
PRODUCTION
AND
PROCESSING
OF
AMYLOID
BETA
AMYLOID
(A(3)
AS
A
THERAPEUTIC
TARGET
IN
ALZHEIMER
'
S
DISEASE
.
49
IVAN
LIEBERBURG
REGULATION
OF
APP
PROCESSING
BY
FIRST
MESSENGERS
.
54
ROGER
M.
NITSCH,
JOHN
H.
GROWDON,
STEVEN
A.
FARBER,
MEIHUA
DENG
AND
RICHARD
J.
WURTMAN
VI
CONTENTS
IN
VITRO
PRODUCTION
OF
AMYLOID
^-PROTEIN:
A
ROUTE
TO
THE
MECHANISM
AND
TREATMENT
OF
ALZHEIMER
'
S
DISEASE
.
62
DENNIS
J.
SELKOE
APOLIPOPROTEIN
E
AND
ALZHEIMER
'
S
DISEASE:
THERAPEUTIC
IMPLICATIONS
.
65
WARREN
J.
STRITTMATTER,
DAVID
Y.
HUANG,
ANN
SAUNDERS,
DONALD
SCHMECHEL,
MARGARET
PERICAK-VANCE,
ALLEN
D.
ROSES,
KARL
H.
WEISGRABER
AND
MICHEL
GOEDERT
APOLIPOPROTEIN
E4
AND
CHOLINERGIC
DYSFUNCTION
IN
ALZHEIMER
'
S
DISEASE
.
72
JUDES
POIRIER,
ISABELLE
AUBERT,
PHILIPPE
BERTRAND,
REMI
QUIRION,
SERGE
GAUTHIER
AND
JOSEPHINE
NALBANTOGLU
PART
TH.
THE
CHOLINERGIC
SYSTEM
OF
HUMAN
BRAIN
BUTYRYLCHOLINESTERASE
IN
ALZHEIMER
'
S
DISEASE
.
79
M.-MARSEL
MESULAM
MODULATING
CHOLINERGIC
NEUROTRANSMISSION
THROUGH
TRANSGENIC
OVEREXPRESSION
OF
HUMAN
CHOLINESTERASES
.
84
HERMONA
SOREQ,
RACHEL
BEERI,
SHLOMO
SEIDMAN,
RINA
TIMBERG,
YAEL
LOEWENSTEIN,
MEIRA
STEMFELD,
CHRISTIAN
ANDRES
AND
MOSHE
SHANI
STRUCTURE-FUNCTION
RELATIONSHIPS
IN
THE
BINDING
OF
REVERSIBLE
INHIBITORS
IN
THE
ACTIVE-SITE
GORGE
OF
ACETYLCHOLINESTERASE
.
88
I.
SILRNAN,
M.
HAREL,
J.
EICHLER,
J.L.
SUSSMAN,
A.
ANSELMET
AND
J.
MASSOULIE
CHOLINERGIC
CHANGES
AND
SYNAPTIC
ALTERATIONS
IN
ALZHEIMER
'
S
DISEASE
.
93
STEVEN
T.
DEKOSKY,
SCOT
D.
STYREN
AND
MARK
E.
O
'
MALLEY
PART
IV.
CHOLINESTERASE
INHIBITORS
IN
AD
TREATMENT
INTRODUCTION
TO
CHOLINESTERASE
INHIBITORS
USED
IN
ALZHEIMER
'
S
DISEASE
THERAPY
.
99
VINOD
KUMAR
CONTENTS
VII
A
PHARMACODYNAMIC
STRATEGY
TO
OPTIMIZE
THE
CLINICAL
RESPONSE
TO
EPTASTIGMINE
(MF-201)
.
103
BRUNO
P.
IMBIMBO
AND
PAOLO
E.
LUCCHELLI
EPTASTIGMINE
(MF-201).
A
DOUBLE-BLIND,
PLACEBO-CONTROLLED,
CLINICAL
TRIAL
IN
ALZHEIMER
DISEASE
PATIENTS
.
108
NICOLA
CANAL,
MASSIMO
FRANCESCHI
AND
THE
ITALIAN
EPTASTIGMINE
INVESTIGATORS
COGNITION
IMPROVEMENT
BY
ORAL
HUPERZINE
A:
A
NOVEL
ACETYLCHOLINESTERASE
INHIBITOR
.
113
XI
CAN
TANG,
ZHI
QI
XIONG,
BO
CHU
QIAN,
ZHI
FANG
ZHOU
AND
CI
LU
ZHANG
IN
VITRO
AND
IN
VIVO
EFFECTS
OF
A
DUAL
INHIBITOR
OF
ACETYLCHOLINESTERASE
AND
MUSCARINIC
RECEPTORS,
CI-1002
.
120
MARK
R.
EMMERLING,
VLAD
E.
GREGOR,
ROY
D.
SCHWARZ,
JEFF
D.
SCHOLTEN,
MICHAEL
J.
CALLAHAN,
CHITASE
LEE,
CATHERINE
J.
MOORE,
CHARLOTTE
RABY,
WILLIAM
J.
LIPINSKI,
JUAN
JAEN
AND
ROBERT
E.
DAVIS
EFFECTS
OF
NOVEL
CHOLINESTERASE
INHIBITORS
BASED
ON
THE
MECHANISM
OF
ENZYME
INHIBITION
.
125
ALBERT
ENZ,
DIETER
MEIER
AND
RENE
SPIEGEL
BIOCHEMISTRY,
PHARMACOKINETICS
AND
PHARMACODYNAMICS
OF
MDL
73,745:
A
POTENT
AND
SELECTIVE
INHIBITOR
OF
ACETYLCHOLINESTERASE
.
131
JEAN-MARIE
HOMSPERGER,
JEAN-NOEL
COLLARD,
DANIEL
SCHIRLIN,
JAMES
DOW,
JEAN-GEORGES
HEYDT
AND
BERTRAND
DULERY
CLINICAL
EXPERIENCE
WITH
MDL
73,745;
PHARMACOKINETICS,
PHARMACODYNAMICS,
AND
CLINICAL
TOLERANCE
IN
NORMAL
VOLUNTEERS
.
137
MARGO
M.
SCHLEMAN,
STEPHEN
S.
SONGER,
OLO
J.
SZYLLEYKO,
RANDALL
D.
SEIFERT
AND
NEAL
R.
CUTLER
GALANTHAMINE
IN
ALZHEIMER
'
S
DISEASE
.
140
HELMUT
KEWITZ,
GORDON
WILCOCK
AND
BONNIE
DAVIS
TACRINE:
AN
OVERVIEW
OF
EFFICACY
IN
TWO
PARALLEL
GROUP
STUDIES
.
145
STEPHEN
I.
GRACON
AND
MARGARET
J.
KNAPP
CLINICAL
UPDATE
OF
VELNACRINE
RESEARCH
.
150
KLAUDIUS
SIEGFRIED
AND
RICH
CIVIL
VIII
CONTENTS
SECOND
AND
THIRD
GENERATION
CHOLINESTERASE
INHIBITORS:
FROM
PRECLINICAL
STUDIES
TO
CLINICAL
EFFICACY
.
155
EZIO
GIACOBINI
AND
GABRIEL
CUADRA
SECOND
AND
THIRD
GENERATION
CHOLINESTERASE
INHIBITORS:
CLINICAL
ASPECTS
.
172
ROBERT
E.
BECKER,
PAMELA
MORIEARTY,
RITA
SURBECK,
LATHA
UNNI,
ANDREW
VARNEY
AND
SANDRA
K.
VICARI
PART
V.
NICOTINIC
AGONISTS
AS
DRUGS
FOR
AD
TREATMENT
NICOTINIC
RECEPTORS
IN
HUMAN
BRAIN
.
181
HANNSJORG
SCHRODER,
ANDREA
WEVERS,
CHRISTINA
BIRTSCH,
MONA
GHOBRIAL,
EZIO
GIACOBINI
AND
ALFRED
MAELICKE
DEVELOPMENT
OF
NICOTINIC
AGONISTS
FOR
THE
TREATMENT
OF
ALZHEIMER
'
S
DISEASE
.
186
PATRICK
M.
LIPPIELLO,
WILLIAM
S.
CALDWELL,
MICHAEL
J.
MARKS
AND
ALLAN
C.
COLLINS
DIE
ROLE
OF
NICOTINIC
SYSTEMS
IN
THE
COGNITIVE
DISORDER
OF
ALZHEIMER
'
S
DISEASE
.
191
I?AUL
A.
NEWHOUSE,
ALEXANDRA
POTTER,
JUNE
CORWIN
AND
ROBERT
LENOX
ABT-418:
A
NOVEL
CHOLINERGIC
CHANNEL
ACTIVATOR
(CHCA)
FOR
THE
POTENTIAL
TREATMENT
OF
ALZHEIMER
'
S
DISEASE
.
196
STEPHEN
P.
AMERIC,
JAMES
P.
SULLIVAN,
MICHAEL
W.
DECKER,
JORGE
D.
BRIONI,
CLARK
A.
BRIGGS,
DIANA
DONNELLY-ROBERTS,
KENNAN
C.
MARSH,
A.
DAVID
RODRIGUES,
DAVID
S.
GARVEY,
MICHAEL
WILLIAMS
AND
JERRY
J.
BUCCAFUSCO
NICOTINE,
CATECHOLAMINES
AND
COGNITIVE
ENHANCEMENT
.
201
JEFFREY
A.
GRAY,
GRIGORY
A.
GRIGORYAN,
CHULY
LEE,
STEPHEN
N.
MITCHELL
AND
HELEN
HODGES
THE
SUBUNIT
SPECIFIC
EFFECTS
OF
NOVEL
ANABASEINE-DERIVED
NICOTINIC
AGENTS
.
206
ROGER
L.
PAPKE,
CHRISTOPHER
M.
DE
FIEBRE,
WILLIAM
KEM
AND
EDWIN
M.
MEYER
SEROTONIN
DEPLETION
DECREASES
THERAPEUTIC
EFFECT
OF
THA
AND
NICOTINE
.
212
PAAVO
J.
RIEKKINEN,
JR.,
MINNA
K.
RIEKKINEN
AND
JOUNI
S.
SIRVIO
CONTENTS
IX
PART
VI.
MUSCARINIC
AGONISTS:
PRECLINICAL
AND
CLINICAL
APPROACHES
SELECTIVE
SIGNALING
VIA
NOVEL
MUSCARINIC
AGONISTS:
IMPLICATIONS
FOR
ALZHEIMER
'
S
DISEASE
TREATMENTS
AND
CLINICAL
UPDATE
.
219
ABRAHAM
FISHER,
ELIAHU
HELDMAN,
DAVID
GURWITZ,
RACHEL
HARING,
YISHAI
KARTON,
HAIM
MESHULAM,
ZIPPORA
PITTEL,
DANIELE
MARCIANO,
ITZHAK
MARCOVITCH,
RACHEL
BRANDEIS,
TERESE
A.
TREVES,
RUTH
VERCHOVSKY,
SONIA
KLIMOWSKY
AND
AMOS
D.
KORCZYN
SELECTIVE
MUSCARINIC
AGONISTS
FOR
ALZHEIMER
DISEASE
TREATMENT
.
224
ROY
D.
SCHWARZ,
MICHAEL
J.
CALLAHAN,
ROBERT
E.
DAVIS,
JUAN
C.
JAEN,
WILLIAM
LIPINSKI,
CHARLOTTE
RABY,
CAROLYN
J.
SPENCER
AND
HAILE
TECLE
XANOMELINE:
AN
EFFICACIOUS
AND
SPECIFIC
ML
RECEPTOR
AGONIST
-
PRECLINICAL
UPDATE
.
229
HARLAN
E.
SHANNON,
FRANK
P.
BYMASTER,
DAVID
O.
CALLIGARO,
BEVERLEY
GREENWOOD,
CHARLES
H.
MITCH,
JOHN
S.
WARD,
PER
SAUERBERG,
PREBEN
OLESEN,
MALCOLM
SHEARDOWN,
MICHAEL
D.B.
SWEDBERG
AND
PETER
D.
SUZDAK
XANOMELINE,
A
SPECIFIC
ML
AGONIST:
EARLY
CLINICAL
STUDIES
.
234
N.C.
BODICK,
A.F.
DELONG,
P.L.
BONATE,
T.
GILLESPIE,
D.P.
HENRY,
J.H.
SATTERWHITE,
R.A.
LUCAS,
J.
HEATON,
G.V.
CARTER,
L.
FARDE,
N.R.
CUTLER,
J.J.
SRAMEK,
R.D.
SEIFERT,
J.J.
CONRAD
AND
T.S.
WARDLE
CI-979/RU
35926:
A
NOVEL
MUSCARINIC
AGONIST
FOR
THE
TREATMENT
OF
ALZHEIMER
'
S
DISEASE
.
239
TONI
M.
HOOVER
PART
VII.
DRUGS
TO
ENHANCE
ACETYLCHOLINE
SYNTHESIS
AND
RELEASE
CHOLINE
METABOLISM,
MEMBRANE
PHOSPHOLIPIDS,
AND
ALZHEIMER
'
S
DISEASE
.
247
STEVEN
A.
FARBER,
BARBARA
E.
SLACK,
ENRICO
DEMICHELI,
RICHARD
J.
WURTMAN,
ROGER
M.
NITSCH,
JOHN
H.
GROWDON,
BRUCE
M.
COHEN,
ANDREW
L.
STOLL
AND
PERRY
F.
RENSHAW
X
CONTENTS
NEUROTRANSMITTER
RELEASE
ENHANCEMENT
AS
A
POSSIBLE
THERAPY
FOR
NEURODEGENERATIVE
DISEASES:
UPDATE
ON
LINOPIRDINE
(DUP996)
.
252
ROBERT
ZACZEK,
ROBERT
J.
CHORVAT,
RICHARD
A.
EARL
AND
S.
WILLIAM
TAM
PART
VIN.
NOOTROPIC
DRUGS
IN
AD
TREATMENT
NOOTROPIC
DRUGS:
THE
GAP
BETWEEN
PRECLINICAL
AND
CLINICAL
RESULTS
.
.
.
259
GIANCARLO
PEPEU,
MARIA
GRAZIA
GIOVANNINI,
ILEANA
MARCONCINI
PEPEU
AND
LUCIANO
BARTOLINI
NOOTROPIC
DRUGS
IN
ALZHEIMER
DISEASE
TREATMENT.
NEW
PHARMACOLOGICAL
STRATEGIES
.
265
TATIANA
A.
VORONINA
THERAPEUTIC
EFFICACY
OF
NOOTROPIC
DRUGS
IN
ALZHEIMER
'
S
DISEASE
AND
AGE
RELATED
COGNITIVE
DYSFUNCTION
.
270
JULIAN
A.
GRAY,
JENNIFER
A.
NAGEL,
ROMAN
AMREIN,
GIORGIO
MARINI
AND
UMBERTO
SENIN
PART
IX.
NEUROTROPHINS,
GROWTH
FACTORS,
AND
NEUROPROTECTION
IN
THE
TREATMENT
OF
ALZHEIMER
'
S
DISEASE
TBWARD
THE
REPAIR
OF
CORTICAL
SYNAPSES
IN
ALZHEIMER
'
S
DISEASE
.
277
A.
CLAUDIO
CUELLO
GANGLIOSIDES
IN
ALZHEIMER
'
S
DISEASE:
EXPERIMENTAL
AND
CLINICAL
DATA
.
284
LARS
SVENNERHOLM
AND
GINO
TOFFANO
PART
X.
EXCITATORY
AMINO
ACIDS,
CA
+
+
CELLULAR
HOMEOSTASIS,
NITRIC
OXIDE,
AND
AD
TREATMENT
EXCITATORY
TRANSMITTER
NEUROTOXICITY
AND
ALZHEIMER
'
S
DISEASE
.
293
JOHN
W.
OLNEY
AND
NURI
B.
FARBER
FREE
INTRACELLULAR
CALCIUM
IN
AGING
AND
ALZHEIMER
'
S
DISEASE
.
299
WALTER
MULLER,
ANNE
ECKERT,
HENRIKE
HARTMANN
AND
HANS
FBRSTL
NITRIC
OXIDE
SYNTHASE
IN
A
LESION
MODEL
OF
ALZHEIMER
'
S
DISEASE
.
304
KIMINOBU
SUGAYA
AND
MICHAEL
MCKINNEY
CONTENTS
XI
PART
XI.
ANTIOXIDANT,
PROTECTIVE,
AND
ANTI-INFLAMMATORY
AGENTS
IN
AD
THERAPY
ANTIOXIDANT
DRUGS
AS
NEUROPROTECTIVE
AGENTS
.
313
ELENA
B.
BURLAKOVA
IMMUNE
MECHANISMS
IN
SENILE
PLAQUE
FORMATION
.
318
PATRICK
L.
MCGEER,
DOUGLAS
G.
WALKER,
OSAMU
YASUHARA,
ANDIS
KLEGERIS
AND
EDITH
G.
MCGEER
INFLAMMATORY
PATHOLOGY
IN
ALZHEIMER
'
S
DISEASE
.
323
SCOTT
D.
WEBSTER
AND
JOSEPH
ROGERS
ALUMINUM
CHELATION
THERAPY
OF
ALZHEIMER
'
S
DISEASE
.
328
DONALD
R.
MCLACHLAN,
THEO
P.A.
KRUCK
AND
WANDA
L.
SMITH
IN
VITRO
EVIDENCE
FOR
THE
USE
OF
ANTIOXIDANTS
IN
ALZHEIMER
'
S
DISEASE
.
334
J.
STEVEN
RICHARDSON,
UJENDRA
KUMAR,
SUBBARAO
V.
KALA,
LIHUA
CHEN
AND
YAN
ZHOU
A
PART
XII.
TREATMENT
OF
BEHAVIORAL
AND
GAIT
DISTURBANCES
PHARMACOLOGIC
MANAGEMENT
OF
AGITATION
AND
DEPRESSION
IN
DEMENTIA
.
343
LON
S.
SCHNEIDER
TREATMENT
WITH
SEROTONERGIC
DRUGS
OF
EMOTIONAL
DISTURBANCES
IN
PATIENTS
WITH
DEMENTIA
DISORDERS
.
349
CARL-GERHARD
GOTTFRIES
GLUTAMATERGIC
HYPOACTIVITY
IN
ALZHEIMER
'
S
DISEASE:
INVESTIGATIVE
AND
THERAPEUTIC
PERSPECTIVES
.
354
PAUL
T.
FRANCIS,
IAIN
P.
CHESSELL,
MARIE-THERESE
WEBSTER,
ANDREW
W.
PROCTER,
MICHELLE
QUME
AND
DAVID
M.
BOWEN
DISTURBANCES
OF
GAIT
IN
PATIENTS
WITH
DEMENTIA
.
359
RODGER
J.
ELBLE
XII
CONTENTS
PART
XM.
NEUROTOXIC
DRUGS,
TRANSGENIC
ANIMALS,
AND
AGING
PRIMATES
AS
MODELS
OF
AD
TREATMENT
THE
CENTRALLY
CHOLINODEFICIENT
ANIMAL
AS
A
MODEL
OF
ALZHEIMER
'
S
DISEASE
(AD)
.
367
ISRAEL
HANIN
ROLE
OF
THE
CARBOXYTERMINUS
OF
THE
ALZHEIMER
AMYLOID
PROTEIN
PRECURSOR
IN
ALZHEIMER
'
S
DISEASE
NEURODEGENERATION
.
375
RACHAEL
L.
NEVE
AND
MICHAEL
R.
KOZLOWSKI
NEUROFILAMENT
PATHOLOGY
IN
ANIMAL
MODELS
FOR
ALZHEIMER
'
S
DISEASE
.
.
.
380
MASATOSHI
TAKEDA,
ATSUO
SEKIYAMA,
GEN
KANAYAMA,
SATOSHI
TANIMUKAI,
TOSHIHISA
TANAKA
AND
TSUYOSHI
NISHIMURA
TRANSGENIC
MICE
AS
A
MODEL
OF
ALZHEIMER
'
S
DISEASE
.
385
LINDA
S.
HIGGINS
AND
BARBARA
CORDELL
AGED
NON-HUMAN
PRIMATES
AS
MODELS
OF
(3-AMYLOIDOSES
.
390
LARY
C.
WALKER
MODEL
STUDIES
OF
THE
ROLE
OF
ANTI-NEUROFILAMENT
ANTIBODIES
IN
NEURODEGENERATION
IN
ALZHEIMER
'
S
DISEASE
.
395
LEA
ORON,
VLADIMIR
DUBOVIK,
MIRA
PERLMAN,
LARISA
NOVITSKY
AND
DANIEL
M.
MICHAELSON
PART
XIV.
USE
OF
IMAGING
TECHNIQUES
(SPECT,
MRI,
PET)
TO
MONITOR
THE
EFFECT
OF
DRUGS
IN
AD
TREATMENT
USE
OF
PET
TECHNIQUE
TO
MONITOR
EFFECT
OF
DRUGS
IN
ALZHEIMER
DISEASE
TREATMENT
.
:
405
AGNETA
NORDBERG
POSITRON
EMISSION
TOMOGRAPHY
WITH
F
11
C]-METHYLTACRINE
AND
I
1
1
C]-PHYSOSTIGMINE
.
413
BERTRAND
TAVITIAN,
SABINA
PAPPATA,
ANTOINETTE
JOBERT,
CHRISTIAN
CROUZEL,
LUIGI
DI
GIAMBERARDINO
AND
ANNA
M.
PLANAS
USE
OF
SPECT
IN
EARLY
DIAGNOSIS
AND
TO
MONITOR
THE
EFFECT
OF
DRUGS
IN
ALZHEIMER
DISEASE
.
417
PHILIPPE
ROBERT,
MICHEL
BENOIT,
GUY
DARCOURT,
OCTAVE
MIGNECO,
JACQUES
DARCOURT
AND
FRANCOISE
BUSSIERE
CONTENTS
XIII
NICOTINIC
STIMULATION
OF
ANTERIOR
REGIONAL
CEREBRAL
GLUCOSE
METABOLISM
IN
ALZHEIMER
'
S
DISEASE:
PRELIMINARY
STUDY
WITH
TRANSDERMAL
PATCHES
.
424
RANDOLPH
W.
PARKS,
CARTER
S.
YOUNG,
ROBERT
F.
RIPPEY,
VALERIE
DANZ,
CATHY
VOHS,
JANE
R.
MATTHEWS,
G.
TODD
COLLINS,
STEVEN
S.
ZIGLER,
PAUL
G.
URYCKI,
PATRICIA
KEIM,
ESPERANZA
KABATAY
AND
ROBERT
E.
BECKER
PART
XV.
CLINICAL
TESTING
OF
EFFICACY
OF
NEW
DRUGS
IN
AD
MINIMAL
EFFICACY
CRITERIA
FOR
MEDICATIONS
IN
ALZHEIMER
DISEASE
.
431
SERGE
GAUTHIER,
HOWARD
FELDMAN
AND
ERICH
MOHR
CLINICAL
TESTING
OF
NEW
DRUGS
FOR
EFFICACY
IN
ALZHEIMER
'
S
DISEASE
.
436
LEON
J.
THAL
INSTRUMENTS
FOR
MEASURING
THE
EFFICACY
OF
TREATMENTS
FOR
ALZHEIMER
'
S
DISEASE
.
441
RICHARD
C.
MOHS,
DEBORAH
B.
MARIN,
CYNTHIA
R.
GREEN
*
AND
KENNETH
L.
DAVIS
PSYCHOMETRIC
STRENGTHS
AND
WEAKNESSES
OF
THE
ALZHEIMER
DISEASE
ASSESSMENT
SCALE
IN
CLINICAL
TESTING:
RECOMMENDATIONS
FOR
IMPROVEMENTS
.
444
RONALD
F.
ZEE,
EDWARD
S.
LANDRETH,
EDEN
BIRD,
ROSEMARY
B.
HARRIS,
RANDALL
ROBBS,
STEPHEN
J.
MARKWELL
AND
DENNIS
Q.
MCMANUS
VALIDATION
OF
INFORMANT-BASED
COGNITIVE
ASSESSMENT
FOR
USE
IN
AUTOPSY
.
450
DENNIS
Q.
MCMANUS,
ROSEMARY
B.
HARRIS
AND
LARRY
F.
HUGHES
PART
XVI.
SOCIO-ECONOMIC
ASPECTS
IN
THE
TREATMENT
OF
ALZHEIMER
'
S
DISEASE
SOCIO-ECONOMIC
ASPECTS
OF
ALZHEIMER
'
S
DISEASE
TREATMENT
.
459
MARCO
TRABUCCHI,
STEFANO
GOVONI
AND
ANGELO
BIANCHETTI
AUTONOMY
IN
ALZHEIMER
DISEASE
.
464
GEORGE
J.
AGICH
XIV
CONTENTS
ECONOMIC
ANALYSIS
OF
ALZHEIMER
'
S
DISEASE
IN
OUTPATIENTS:
IMPACT
OF
SYMPTOM
SEVERITY
.
470
E.J.
SOUETRE,
W.
QING,
I.
VIGOUREUX,
H.
LOZET,
J.F.
DARTIGUES,
L.
LACOMBLEZ
AND
C.
DEROUSENE
PART
XVH.
ALZHEIMER
DISEASE
TREATMENT:
THE
FUTURE
AD
TREATMENT:
THE
FUTURE
.
481
PETER
J.
WHITEHOUSE
THERAPEUTIC
STRATEGIES
IN
ALZHEIMER
'
S
DISEASE
.
485
LARS-OLOF
WAHLUND,
RICHARD
F.
COWBUM,
BENGT
WINBLAD
AND
LARS
LANNFELT
NEW
STRATEGIES
FOR
ALZHEIMER
'
S
DISEASE
TREATMENT:
PLEIOTROPIC
DRUGS
AND
MULTIFACTORIAL
INTERVENTION
.
493
RAMON
CACABELOS
AUTHOR
INDEX
.
499
SUBJECT
INDEX
.
503 |
| any_adam_object | 1 |
| author_GND | (DE-588)114737282 |
| building | Verbundindex |
| bvnumber | BV009962156 |
| callnumber-first | R - Medicine |
| callnumber-label | RC523 |
| callnumber-raw | RC523 |
| callnumber-search | RC523 |
| callnumber-sort | RC 3523 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | YG 4015 |
| ctrlnum | (OCoLC)31011493 (DE-599)BVBBV009962156 |
| dewey-full | 616.8/31 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.8/31 |
| dewey-search | 616.8/31 |
| dewey-sort | 3616.8 231 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 c 4500</leader><controlfield tag="001">BV009962156</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">941223s1994 d||| |||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">943342449</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0817637575</subfield><subfield code="9">0-8176-3757-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3764337575</subfield><subfield code="9">3-7643-3757-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)31011493</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV009962156</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-29T</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-188</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC523</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.8/31</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YG 4015</subfield><subfield code="0">(DE-625)153494:12921</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Alzheimer disease</subfield><subfield code="b">therapeutic strategies</subfield><subfield code="c">Ezio Giacobini ... ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boston</subfield><subfield code="b">Birkhäuser</subfield><subfield code="c">1994</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIV, 509 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Advances in Alzheimer disease therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alzheimer, Maladie d' - Chimiothérapie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alzheimer, Maladie d' - Physiopathologie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alzheimer, Maladie d' - Traitement</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alzheimer Disease</subfield><subfield code="x">physiopathology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alzheimer Disease</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alzheimer's disease</subfield><subfield code="x">Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alzheimer's disease</subfield><subfield code="x">Pathophysiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alzheimer's disease</subfield><subfield code="x">Treatment</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Alzheimerkrankheit</subfield><subfield code="0">(DE-588)4112510-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Alzheimerkrankheit</subfield><subfield code="0">(DE-588)4112510-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Alzheimerkrankheit</subfield><subfield code="0">(DE-588)4112510-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Giacobini, Ezio</subfield><subfield code="d">1929-</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)114737282</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006602217&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-006602217</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV009962156 |
| illustrated | Illustrated |
| indexdate | 2024-08-19T00:35:22Z |
| institution | BVB |
| isbn | 0817637575 3764337575 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-006602217 |
| oclc_num | 31011493 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-29 DE-29T DE-19 DE-BY-UBM DE-188 |
| owner_facet | DE-355 DE-BY-UBR DE-29 DE-29T DE-19 DE-BY-UBM DE-188 |
| physical | XIV, 509 S. graph. Darst. |
| publishDate | 1994 |
| publishDateSearch | 1994 |
| publishDateSort | 1994 |
| publisher | Birkhäuser |
| record_format | marc |
| series2 | Advances in Alzheimer disease therapy |
| spelling | Alzheimer disease therapeutic strategies Ezio Giacobini ... ed. Boston Birkhäuser 1994 XIV, 509 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Advances in Alzheimer disease therapy Alzheimer, Maladie d' - Chimiothérapie Alzheimer, Maladie d' - Physiopathologie Alzheimer, Maladie d' - Traitement Alzheimer Disease physiopathology Alzheimer Disease therapy Alzheimer's disease Chemotherapy Alzheimer's disease Pathophysiology Alzheimer's disease Treatment Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Therapie (DE-588)4059798-2 gnd rswk-swf Alzheimerkrankheit (DE-588)4112510-1 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Alzheimerkrankheit (DE-588)4112510-1 s Therapie (DE-588)4059798-2 s DE-604 Pharmakotherapie (DE-588)4076066-2 s Giacobini, Ezio 1929- Sonstige (DE-588)114737282 oth DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006602217&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Alzheimer disease therapeutic strategies Alzheimer, Maladie d' - Chimiothérapie Alzheimer, Maladie d' - Physiopathologie Alzheimer, Maladie d' - Traitement Alzheimer Disease physiopathology Alzheimer Disease therapy Alzheimer's disease Chemotherapy Alzheimer's disease Pathophysiology Alzheimer's disease Treatment Pharmakotherapie (DE-588)4076066-2 gnd Therapie (DE-588)4059798-2 gnd Alzheimerkrankheit (DE-588)4112510-1 gnd |
| subject_GND | (DE-588)4076066-2 (DE-588)4059798-2 (DE-588)4112510-1 (DE-588)4143413-4 |
| title | Alzheimer disease therapeutic strategies |
| title_auth | Alzheimer disease therapeutic strategies |
| title_exact_search | Alzheimer disease therapeutic strategies |
| title_full | Alzheimer disease therapeutic strategies Ezio Giacobini ... ed. |
| title_fullStr | Alzheimer disease therapeutic strategies Ezio Giacobini ... ed. |
| title_full_unstemmed | Alzheimer disease therapeutic strategies Ezio Giacobini ... ed. |
| title_short | Alzheimer disease |
| title_sort | alzheimer disease therapeutic strategies |
| title_sub | therapeutic strategies |
| topic | Alzheimer, Maladie d' - Chimiothérapie Alzheimer, Maladie d' - Physiopathologie Alzheimer, Maladie d' - Traitement Alzheimer Disease physiopathology Alzheimer Disease therapy Alzheimer's disease Chemotherapy Alzheimer's disease Pathophysiology Alzheimer's disease Treatment Pharmakotherapie (DE-588)4076066-2 gnd Therapie (DE-588)4059798-2 gnd Alzheimerkrankheit (DE-588)4112510-1 gnd |
| topic_facet | Alzheimer, Maladie d' - Chimiothérapie Alzheimer, Maladie d' - Physiopathologie Alzheimer, Maladie d' - Traitement Alzheimer Disease physiopathology Alzheimer Disease therapy Alzheimer's disease Chemotherapy Alzheimer's disease Pathophysiology Alzheimer's disease Treatment Pharmakotherapie Therapie Alzheimerkrankheit Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006602217&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT giacobiniezio alzheimerdiseasetherapeuticstrategies |